Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates
In our fifth webinar of this series, we welcome Joe Costa, COO of Wedgewood Pharmacy, to discuss the effects of the COVID-19 pandemic on the veterinary compounding pharmaceutical industry.
In our fourth webinar of this series, we welcome Dr. Barbara Kitchell, renowned veterinary oncologist, as she discusses repurposed and translational (human and animal) drugs amidst the COVID-19 pandemic.Webinars
Dr. Schwartz is the Chair of Department of Surgery, Soft Tissue & Orthopedics at the Animal Medical Center, the largest animal hospital in NY. Dr. Schwartz shared how her hospital is handling the logistical, medical, and emotional challenges posed by the current situation.Webinars
Dr. London is a global leader in veterinary targeted therapies. She discusses potential risks to veterinary staff, the value of targeted therapy in times of constrained PPE resources, and the effects of COVID-19 on research activity.Webinars
Dr. Michael J Blackwell, DVM, MPH, a former USPHS Assistant Surgeon General, joins us to discuss the federal response to coronavirus and its implications on veterinary medicine.Webinars
In the wake of the COVID-19 pandemic, there has been an uptick in demand for at-home oral targeted therapies. With it, came increased interest in the side effect profile of these therapies.
The COVID-19 pandemic is evolving quickly and you need to find information at the appropriate depth and credibility level. To that end we have started a webinar series to address the academic and practical aspects of the COVID-19 crisis as they pertain to the veterinary world.Webinars
Welcome to the FidoCure® blog for the veterinary community. We had planned to launch this section where our team of scientists and clinicians would share short written articles about the science behind FidoCure®.